| Not Yet Recruiting | A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-coll HIV Infections | Phase 3 | 2026-05-08 |
| Not Yet Recruiting | A Study to Investigate the Safety and PK of VH4770359 in Healthy Participants HIV Infections | Phase 1 | 2026-04-07 |
| Not Yet Recruiting | A Study to Investigate Cabotegravir for Neonates Exposed to HIV-1 HIV Infections | Phase 1 / Phase 2 | 2026-03-17 |
| Recruiting | A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) HIV Infections | Phase 2 | 2026-02-11 |
| Active Not Recruiting | A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity HIV Infections | Phase 1 | 2025-07-10 |
| Completed | A Study to Evaluate VH4524184 Tablet Absorption, Effects of Food, and Interactions With Other Drugs in Healthy HIV Infections | Phase 1 | 2025-07-07 |
| Active Not Recruiting | A Study to Investigate if Long Acting Cabotegravir (CAB) and Lenacapavir (LEN) Injections Are Tolerable and Ac HIV Infections | Phase 1 | 2025-04-22 |
| Active Not Recruiting | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) HIV Infections | Phase 1 | 2025-01-17 |
| Active Not Recruiting | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-A HIV Infections | Phase 2 | 2024-12-20 |
| Recruiting | A Study to Assess the Safety, Tolerability, and Pharmacokinetics of VH4011499 Compared to Placebo in Adults Wi HIV Infections | Phase 1 | 2024-12-16 |
| Recruiting | A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given HIV Infections | Phase 3 | 2024-12-02 |
| Active Not Recruiting | A Study to Assess the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VH4527079) in Healthy Adults HIV Infections | Phase 1 | 2024-10-02 |
| Withdrawn | VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability HIV Infections | Phase 1 | 2024-08-02 |
| Recruiting | Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants a HIV Infections | Phase 3 | 2024-05-14 |
| Completed | A Study to Investigate the Effect of Food on the Bioavailability of a Capsid Inhibitor (CAI) in Male and Femal HIV Infections | Phase 1 | 2024-04-17 |
| Recruiting | First Time in Human Study of Long Acting VH4524184 Formulations HIV Infections | Phase 1 | 2024-03-21 |
| Completed | A Study to Investigate the Potential Drug-Drug Interaction Between VH4524184 and Oral Contraceptive (Loestrin) HIV Infections | Phase 1 | 2024-03-06 |
| Active Not Recruiting | A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared HIV, HIV Infections | Phase 3 | 2024-02-09 |
| Completed | VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1 HIV Infections | Phase 2 | 2024-02-07 |
| Terminated | A Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in in Trea HIV Infections | Phase 2 | 2023-12-21 |
| Completed | A Study to Investigate the Relative Bioavailability and Food Effect of an Oral Capsid Inhibitor Tablet Formula HIV Infections | Phase 1 | 2023-12-18 |
| Completed | Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults HIV Infections | Phase 2 | 2023-10-25 |
| Completed | A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Two Different Formulations of Long-ac HIV Infections | Phase 1 | 2023-09-12 |
| Active Not Recruiting | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Suspension Injection of Investi HIV Infections | Phase 1 | 2023-08-24 |
| Active Not Recruiting | A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of C HIV Infections | Phase 2 | 2023-08-17 |
| Active Not Recruiting | A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a HIV Infections | Phase 3 | 2023-07-06 |
| Recruiting | Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics HIV Infections | Phase 1 / Phase 2 | 2023-07-06 |
| Completed | A Study to Assess the Food Effect and the Relative Bioavailability of the Cabotegravir (CAB) Pediatric Dispers HIV Infections | Phase 1 | 2023-03-23 |
| Active Not Recruiting | A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants HIV, HIV Infections | Phase 3 | 2023-01-31 |
| Completed | A Study to Investigate Safety, Tolerability, and Pharmacokinetics (PK) of VH4524184 and the Potential for Chan HIV Infections | Phase 1 | 2022-12-02 |
| Completed | Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Human Immunodeficiency Virus Type 1 (HIV-1) | Phase 3 | 2022-11-08 |
| Completed | A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women HIV Infections | Phase 4 | 2022-10-28 |
| Completed | First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4011499 i HIV Infections | Phase 1 | 2022-10-03 |
| Recruiting | A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant HIV Infections | Phase 1 | 2022-06-14 |
| Completed | A Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-Volume PrEP Site HIV Infections | Phase 4 | 2022-05-18 |
| Completed | A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of VH3810109 (Also Known as GSK3810109 HIV Infections | Phase 1 | 2022-02-23 |
| Completed | First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4004280 i HIV Infections | Phase 1 | 2021-12-13 |
| Completed | Study Using CABENUVA™ for the Treatment of Human Immunodeficiency Virus (HIV)-1, Administered in Infusion Cent HIV Infections | Phase 4 | 2021-11-18 |
| Completed | A Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected Parti Human Immunodeficiency Virus Type 1 (HIV-1) | Phase 3 | 2021-10-28 |
| Terminated | A Clinical Trial of GSK3640254 + Dolutegravir (DTG) in Human Immunodeficiency Virus-1 Infected Treatment-naive HIV Infections | Phase 2 | 2021-08-18 |
| Completed | A Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A in Viremic Human Immunodefici HIV Infections | Phase 2 | 2021-06-22 |
| Completed | A Food-effect Study of the Pediatric Dispersible Tablet Formulations of TRIUMEQ® and DOVATO® in Healthy Adult HIV Infections | Phase 1 | 2021-05-07 |
| Completed | A Relative Bioavailability and Food-Effect Study of the Fixed Dose Combination of GSK3640254 and Dolutegravir HIV Infections | Phase 1 | 2021-04-21 |
| Completed | Low-dose Fostemsavir Extended Release Relative Bioavailability Study HIV Infections | Phase 1 | 2021-03-05 |
| Completed | Evaluation of Pharmacokinetic Interaction Between GSK3640254 and Caffeine, Metoprolol, Montelukast, Flurbiprof HIV Infections | Phase 1 | 2020-12-16 |
| Terminated | A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive Adu HIV Infections | Phase 2 | 2020-11-18 |
| Completed | A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA V HIV Infections | Phase 3 | 2020-11-09 |
| Completed | Effect of Therapeutic and Supratherapeutic Oral Doses of GSK3640254 on Cardiac Conduction Compared to Placebo HIV Infections | Phase 1 | 2020-11-09 |
| Completed | Drug-drug Interaction (DDI) Study of GSK3640254 With Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR) HIV Infections | Phase 1 | 2020-10-28 |
| Completed | A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Inject HIV Infections | Phase 3 | 2020-09-28 |
| Completed | Pharmacokinetics and Metabolism of 14 Carbon [14C]-GSK3640254 HIV Infections | Phase 1 | 2020-09-24 |
| Completed | Pharmacokinetic Study of Cabotegravir and Rilpivirine Long-acting Intramuscular Injections in Healthy Adult Pa HIV Infections | Phase 1 | 2020-09-16 |
| Completed | Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milli HIV Infections | Phase 1 | 2020-07-31 |
| Completed | GSK3739937 First-Time-In-Human (FTIH) Study in Healthy Volunteers HIV Infections | Phase 1 | 2020-07-31 |
| Completed | A Relative Bioavailability and Food-Effect Study of GSK3640254 Tablet and Capsule Formulations in Healthy Part HIV Infections | Phase 1 | 2020-01-27 |
| Completed | 'COMBINE-2': Real-world Evidence for Effectiveness of Two Drug Regimen, Antiretroviral Therapy With Integrase HIV Infections | — | 2019-11-18 |
| Recruiting | Study to Define Safety and Effectiveness of Dolutegravir (DTG) Use in Human Immunodeficiency Virus (HIV) Posit HIV Infections | — | 2019-11-18 |
| Completed | Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current Antiretroviral Regimen in HIV-1 HIV Infections | Phase 3 | 2019-11-11 |
| Terminated | A Relative Bioavailability and Food-Effect Study of GSK3640254 Tablet and Capsule Formulations in Healthy Part HIV Infections | Phase 1 | 2019-10-08 |
| Completed | Study to Identify and Determine Best Implementation Practices for Injectable Cabotegravir+Rilpivirine in the U HIV Infections | Phase 3 | 2019-07-08 |
| Completed | Rapid Test and Treat Dolutegravir Plus Lamivudine Study in Newly Diagnosed Human Immunodeficiency Virus (HIV)- HIV Infections | Phase 3 | 2019-07-02 |
| Terminated | Evaluation of the Safety, Tolerability and Pharmacokinetics (PK) of GSK3732394 First-Time-in-Human (FTIH) Stud HIV Infections | Phase 1 | 2019-06-17 |
| Completed | Study to Evaluate Pharmacokinetics, Safety and Tolerability of Dolutegravir and Rilpivirine (JULUCA™) 50 Milli HIV Infections | Phase 1 | 2019-06-17 |
| Completed | Effect of GSK3640254 on the Pharmacokinetics of a Combination Oral Contraceptive HIV Infections | Phase 1 | 2019-06-13 |
| Completed | Dolutegravir Pediatric Liquid Formulation Study HIV Infections | Phase 1 | 2019-05-07 |
| Completed | Safety and Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Therapy-naive Human Immunodeficiency Virus-1 (HIV- HIV Infections | Phase 3 | 2019-05-06 |
| Completed | Study to Evaluate the Effect of GSK3640254 on the Pharmacokinetics of Tenofovir Alafenamide/Emtricitabine HIV Infections | Phase 1 | 2019-02-11 |
| Completed | A Proof of Concept Study of GSK3640254 in Human Immunodeficiency Virus-1 (HIV-1) Infected Treatment-naive Adul HIV Infections | Phase 2 | 2019-01-31 |
| Completed | Study to Evaluate the Pharmacokinetic (PK) Interactions Between GSK3640254 and Dolutegravir (DTG) HIV Infections | Phase 1 | 2019-01-23 |
| Completed | Description of Real World Antiviral Effectiveness and Sustainability of the 2-Drug Regimen Dolutegravir + Lami HIV Infections | — | 2018-11-08 |
| Completed | Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) HIV Infections | Phase 2 | 2018-09-24 |
| Completed | Dolutegravir/Rilpivirine, Antiretroviral Efficacy Study Using Real-world Data in Subjects With Human Immunodef HIV Infections | — | 2018-06-25 |
| Completed | A Study to Compare the Relative Bioavailability of Two Different Formulations of GSK3640254 HIV Infections | Phase 1 | 2018-06-18 |
| Completed | A Safety, Tolerability, Acceptability, and Pharmacokinetic (PK) Study of Cabotegravir (CAB) in Healthy Human I HIV Infections | Phase 1 | 2018-04-10 |
| Completed | To Assess the Relative Bioavailability (BA) of TRIUMEQ® and Dolutegravir and Lamivudine (DTG/3TC) Pediatric Di HIV Infections | Phase 1 | 2018-02-26 |
| Completed | Real-world Insights of People With Human Immunodeficiency Virus (HIV) Infection HIV Infections | — | 2018-01-18 |
| Completed | Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus HIV Infections | Phase 3 | 2018-01-18 |
| Active Not Recruiting | Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV HIV Infections | Phase 3 | 2017-10-27 |
| Completed | GSK3640254 First Time in Human (FTIH) Study in Healthy Volunteers Infection, Human Immunodeficiency Virus, HIV Infections | Phase 1 | 2017-09-19 |
| Completed | Incidence of Human Immunodeficiency Virus-1 (HIV-1) Infection in HIV-1 Uninfected High Risk Men Who Have Sex W Infection, Human Immunodeficiency Virus, HIV Infections | — | 2017-08-31 |
| Completed | Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019 HIV Infections | Phase 3 | 2017-06-06 |
| Completed | Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects Infection, Human Immunodeficiency Virus, HIV Infections | Phase 1 | 2017-06-06 |
| Completed | Bioavailability Study of 10 Milligram (mg) and 5 mg Tablets Versus Conventional Tablets of Dolutegravir HIV Infections | Phase 1 | 2017-05-03 |
| Completed | Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and Lamivudine Infection, Human Immunodeficiency Virus | Phase 1 | 2017-03-27 |
| Completed | Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers Infection, Human Immunodeficiency Virus, HIV Infections | Phase 1 | 2017-02-27 |
| Completed | Phase 4 Study of Dolutegravir (DTG) in Russian Federation Infection, Human Immunodeficiency Virus, HIV Infections | Phase 4 | 2016-12-08 |
| Active Not Recruiting | Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-act Infection, Human Immunodeficiency Virus, HIV Infections | Phase 3 | 2016-10-28 |
| Active Not Recruiting | Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivi HIV Infections | Phase 3 | 2016-10-27 |
| Completed | Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible Tablet Infection, Human Immunodeficiency Virus | Phase 1 | 2016-09-01 |
| Completed | A Study of the Relative Bioavailability of BMS-626529 Administered as BMS-663068 From 150mg Low-dose Extended- Infection, Human Immunodeficiency Virus | Phase 1 | 2016-08-12 |
| Completed | An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Teno Infection, Human Immunodeficiency Virus, HIV Infections | Phase 3 | 2016-07-21 |
| Completed | An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegrav Infection, Human Immunodeficiency Virus, HIV Infections | Phase 3 | 2016-07-18 |
| Completed | A Study to Evaluate the Effect of High Fat Meal on Cabotegravir Infection, Human Immunodeficiency Virus | Phase 1 | 2016-06-01 |
| Completed | Bioequivalence Study of a Fixed-dose Combination (FDC) of Dolutegravir (DTG) and Rilpivirine (RPV) Infection, Human Immunodeficiency Virus, HIV Infections | Phase 1 | 2016-05-11 |
| Completed | Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations Infection, Human Immunodeficiency Virus | Phase 1 | 2016-05-01 |
| Completed | A Study to Evaluate the Effect of BMS-955176 on Pharmacokinetics of Dolutegravir and the Effect of Dolutegravi Infection, Human Immunodeficiency Virus | Phase 1 | 2016-04-01 |
| Completed | Absolute Bioavailability of BMS-626529 After Oral and Intravenous Dosing Infection, Human Immunodeficiency Virus | Phase 1 | 2016-03-15 |
| Completed | A Study of the Pharmacokinetics and Safety of BMS-663068 Administered in Subjects With Normal Renal Function a HIV Infections | Phase 1 | 2016-02-26 |
| Completed | A Study to Assess the Effect of High Fat Meal and Increased Gastric pH on the Bioavailability of an Extended R Infection, Human Immunodeficiency Virus | Phase 1 | 2016-01-27 |
| Completed | A Study to Assess the Drug-drug Interaction of BMS 663068 With Methadone and Also With Buprenorphine/Naloxone Infection, Human Immunodeficiency Virus | Phase 1 | 2016-01-12 |
| Completed | Taste Properties of HIV Inhibitor HIV Infections | Phase 1 | 2016-01-05 |
| Completed | A Phase IV, Open Label, 4-period Cross-over Study to Investigate a Drug Interaction Between Lamivudine and Sor Infection, Human Immunodeficiency Virus | Phase 4 | 2016-01-01 |
| Completed | Study on Effects of BMS-955176 on the Pharmacokinetics of Probe Substrates HIV Infections | Phase 1 | 2015-11-09 |
| Completed | THE EFFECT OF CYP3A5 GENOTYPE ON THE PHARMACOKINETICS OF MARAVIROC Healthy Subjects | Phase 1 | 2015-11-06 |
| Terminated | A Study to Determine the Effect of Multiple Doses of BMS-955176 on the Electrocardiograph of Healthy Subjects Infection, Human Immunodeficiency Virus | Phase 1 | 2015-10-19 |
| Completed | Pharmacokinetics, Safety and Tolerability Study of Abacavir/ Dolutegravir/ Lamivudine Fixed-dose Combination T Infection, Human Immunodeficiency Virus | Phase 1 | 2015-10-01 |
| Completed | Bioavailability of BMS-626529 in Healthy Subjects From Prototype Low Dose Extended Release Formulations (Part Infection, Human Immunodeficiency Virus | Phase 1 | 2015-08-03 |
| Completed | Pharmacokinetics Study of GSK1265744 in Subjects With Severe Renal Impairment Infection, Human Immunodeficiency Virus, HIV Infections | Phase 1 | 2015-07-13 |
| Terminated | Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults HIV Infections | Phase 2 | 2015-07-08 |
| Completed | A Drug-drug Interaction Study Between BMS-663068 and Oral Contraceptives in Healthy Female Volunteers (DDI) Infection, Human Immunodeficiency Virus | Phase 1 | 2015-07-07 |
| Completed | A Open-label, Drug-Drug Interaction With Maraviroc (DDI) Infection, Human Immunodeficiency Virus | Phase 1 | 2015-07-07 |
| Completed | Effect of Rifampin (RIF) on the Pharmacokinetics (PK) of Oral Cabotegravir (CAB) in Healthy Subjects Infection, Human Immunodeficiency Virus | Phase 1 | 2015-07-01 |
| Completed | A Study to Evaluate Pharmacokinetic (PK) and Safety of GSK1265744 in Subjects With Hepatic Impairment and Cont HIV Infections | Phase 1 | 2015-06-22 |
| Completed | Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a T HIV Infections | Phase 3 | 2015-06-12 |
| Terminated | Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults Infection, Human Immunodeficiency Virus | Phase 2 | 2015-05-12 |
| Completed | Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Vir HIV Infections | Phase 3 | 2015-04-21 |
| Completed | Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Vir HIV Infections | Phase 3 | 2015-04-14 |
| Completed | Relative Bioavailability Study of Phase III Tablet Formulation of Cabotegravir Infection, Human Immunodeficiency Virus | Phase 1 | 2015-03-01 |
| Active Not Recruiting | Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients HIV Infections | Phase 3 | 2015-02-23 |
| Completed | Prospective Non-Interventional Observational Study of Use of TRIUMEQ and Corresponding Monitoring Measures in HIV Infections | — | 2015-02-19 |
| Completed | Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in He Infection, Human Immunodeficiency Virus | Phase 1 | 2015-02-01 |
| Completed | Single-dose Pharmacokinetics of BMS-626529, Administered as BMS-663068, in Subjects With Hepatic Impairment Co Infection, Human Immunodeficiency Virus | Phase 1 | 2015-01-29 |
| Completed | Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosi Infection, Human Immunodeficiency Virus, HIV Infections | Phase 3 | 2015-01-23 |
| Completed | ING200336, Pharmacokinetic and Safety Study in Pregnant Women With Human Immuno Virus Infection Infection, Human Immunodeficiency Virus, HIV Infections, Arthralgia | Phase 3 | 2014-12-17 |
| Completed | Comparative Efficacy and Safety Study of Dolutegravir and Lopinavir/Ritonavir in Second-line Treatment HIV Infections | Phase 3 | 2014-12-11 |
| Completed | A Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers (DDI) Infection, Human Immunodeficiency Virus | Phase 1 | 2014-11-05 |
| Completed | Food Effect Study With BMS-955176 Infection, Human Immunodeficiency Virus | Phase 1 | 2014-10-23 |
| Completed | PRJ2203: Dolutegravir Post Authorization Safety Study (PASS) Infection, Human Immunodeficiency Virus I | — | 2014-09-30 |
| Completed | Study on Pharmacokinetics HIV Infections | Phase 1 | 2014-09-05 |
| Completed | Study of the Absorption, Metabolism, and Route of Elimination of a Novel Class of Anti-HIV 1 Drugs (BMS-955176 HIV Infections | Phase 1 | 2014-08-08 |
| Completed | Study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Levonorgestrel and Ethinyl Estradio Infections, Human Immunodeficiency Virus and Hepatitis | Phase 1 | 2014-08-01 |
| Completed | Bioavailability Study of a Dolutegravir Dispersible Tablet and Effect of Different Types of Water on the Dispe Infection, Human Immunodeficiency Virus | Phase 1 | 2014-07-01 |
| Completed | Study to Evaluate the Effect of Food on the Pharmacokinetics of BMS-626529 Infection, Human Immunodeficiency Virus | Phase 1 | 2014-06-24 |
| Completed | Study of Combined Oral Contraceptive Effects in Female Subjects Infection, Human Immunodeficiency Virus | Phase 1 | 2014-06-02 |
| Completed | Drug-drug Interaction (DDI) Rifabutin Infection, Human Immunodeficiency Virus | Phase 1 | 2014-05-14 |
| Completed | A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Fo Infection, Human Immunodeficiency Virus, HIV Infections | Phase 2 | 2014-04-28 |
| Completed | A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abaca Infection, Human Immunodeficiency Virus | Phase 3 | 2014-04-01 |
| Completed | Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodefic Infection, Human Immunodeficiency Virus | Phase 2 | 2014-03-27 |
| Completed | Relative Bioavailability Study With BMS-955176 Infection, Human Immunodeficiency Virus | Phase 1 | 2014-03-25 |
| Completed | A Prospective, Non-interventional Study of the Use of Dolutegravir as Part of Combination Antiretroviral Thera Infection, Human Immunodeficiency Virus | — | 2014-03-04 |
| Completed | Study to Evaluate the Drug Interaction Between Dolutegravir (DTG) and Daclatasvir (DCV) in Healthy Adult Subje Infection, Human Immunodeficiency Virus | Phase 1 | 2014-03-01 |
| Completed | DDI Study of BMS-663068 With Etravirine (ETR) and/or Darunavir (DVR) + Ritonavir (RTV) Infection, Human Immunodeficiency Virus | Phase 1 | 2014-02-01 |
| Completed | A Study to Assess The Relative Bioavailability of New Tablet Formulations of GSK1265744 in Healthy Adult Subje Infection, Human Immunodeficiency Virus | Phase 1 | 2014-02-01 |
| Completed | Effect of Dolutegravir on Metformin Pharmacokinetics in Healthy Adult Subjects Infection, Human Immunodeficiency Virus | Phase 1 | 2014-02-01 |
| Completed | Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction Infection, Human Immunodeficiency Virus | Phase 1 | 2014-01-01 |
| Completed | Effect of Carbamazepine on Dolutegravir Pharmacokinetics in Healthy Adult Subjects Infection, Human Immunodeficiency Virus | Phase 1 | 2013-10-01 |
| Completed | A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodefi Infection, Human Immunodeficiency Virus, HIV Infections | Phase 3 | 2013-08-22 |
| Completed | An Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1265744 Administered as a Sing HIV-associated Lipodystrophy Syndrome | Phase 1 | 2013-05-01 |
| Completed | Study to Evaluate a HIV Drug for the Treatment of HIV Infection Infection, Human Immunodeficiency Virus, HIV Infections | Phase 2 | 2013-04-04 |
| Completed | A Randomized Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 Long Acting Parent Infection, Human Immunodeficiency Virus | Phase 1 | 2013-01-01 |
| Completed | A Study to Evaluate the Effects of Calcium Carbonate and Ferrous Fumarate on Pharmacokinetics of Dolutegravir Infection, Human Immunodeficiency Virus | Phase 1 | 2012-12-01 |
| Completed | Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immun Infection, Human Immunodeficiency Virus, HIV Infections | Phase 2 | 2012-08-06 |
| Completed | Relative Bioavailability Study of GSK1265744 Formulations Infections, Human Immunodeficiency Virus and Hepatitis | Phase 1 | 2012-08-01 |
| Completed | Estimate the Effect of Telaprevir and Boceprevir on Maraviroc Pharmacokinetics in Healthy Subjects Healthy | Phase 1 | 2012-07-01 |
| Completed | Dolutegravir Expanded Access Study Infection, Human Immunodeficiency Virus, HIV Infections | N/A | 2012-06-14 |
| Completed | Evaluation of the Bioequivalence of a Combined Formulated Tablet Infection, Human Immunodeficiency Virus | Phase 1 | 2012-06-01 |
| Completed | A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Dose Administration of Long-Act Infection, Human Immunodeficiency Virus | Phase 1 | 2012-05-01 |
| Completed | Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegrav HIV Infections | Phase 3 | 2012-04-18 |
| Completed | A Study to Evaluate the Effect of Boceprevir and Telaprevir on Dolutegravir Pharmacokinetics in Healthy Adult Infection, Human Immunodeficiency Virus | Phase 1 | 2012-03-01 |
| Completed | A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infection, Human Immunodeficiency Virus | Phase 3 | 2012-01-01 |
| Completed | Methadone-Dolutegravir (DTG - GSK1349572) Drug Interaction Study. Infections, Human Immunodeficiency Virus and Hepatitis | Phase 1 | 2011-12-01 |
| Completed | Drug Interaction Study Between Dolutegravir and an Oral Contraceptive Containing Norgestimate and Ethinylestra Infection, Human Immunodeficiency Virus | Phase 1 | 2011-12-01 |
| Completed | A Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 and Rilpivirine and Dolutegravir and Rilpivi Infections, Human Immunodeficiency Virus and Hepatitis | Phase 1 | 2011-11-01 |
| Completed | Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Infection, Human Immunodeficiency Virus | Phase 3 | 2011-10-31 |
| Completed | Drug Interaction Study Between Dolutegravir and Prednisone Infection, Human Immunodeficiency Virus | Phase 1 | 2011-09-01 |
| Terminated | Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral- HIV-1 | Phase 3 | 2011-09-01 |
| Completed | Drug Exposure Registry for GSK2248761, an Investigational NNRTI HIV Infections | — | 2011-07-29 |
| Completed | HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections Infection, Human Immunodeficiency Virus | Phase 2 | 2011-07-26 |
| Completed | Dolutegravir Renal Impairment Study Infection, Human Immunodeficiency Virus | Phase 1 | 2011-06-01 |
| Completed | Combivir And Maraviroc In Antiretroviral Naive Subjects In Russia HIV | Phase 4 | 2011-06-01 |
| Completed | Relative Bioavailability Study of a Pediatric Granule Formulation of Dolutegravir Infections, Human Immunodeficiency Virus and Herpesviridae | Phase 1 | 2011-06-01 |
| Completed | Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets Healthy Subjects, Infection, Human Immunodeficiency Virus | Phase 1 | 2011-06-01 |
| Completed | A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B HIV Coinfection | Phase 4 | 2011-05-18 |
| Completed | Phase 1, Open Label, Two Arm, Fixed Sequence Study to Evaluate the Effect of Rifampin and Rifabutin on GSK1349 Infection, Human Immunodeficiency Virus | Phase 1 | 2011-05-01 |
| Completed | A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Conta Infection, Human Immunodeficiency Virus | Phase 3 | 2011-05-01 |
| Completed | A Study to Investigate the Pharmacokinetics, Safety and Tolerability of GSK1349572 (Dolutegravir, DTG) in Heal Infection, Human Immunodeficiency Virus | Phase 1 | 2011-04-01 |
| Completed | Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects Healthy | Phase 1 | 2011-04-01 |
| Withdrawn | A Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1349572 Pharmacokinetics in Healthy Adult Subject Infection, Human Immunodeficiency Virus I | Phase 1 | 2011-03-01 |
| Completed | A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial Infection, Human Immunodeficiency Virus I | Phase 3 | 2011-02-01 |
| Withdrawn | A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK2248761 Administered as an Oral Infection, Human Immunodeficiency Virus | Phase 1 | 2011-01-01 |
| Completed | GSK1349572 Hepatic Impairment Study Healthy Subjects, Hepatic Impairment, Infection, Human Immunodeficiency Virus | Phase 1 | 2010-11-19 |
| Terminated | Dose-finding Study of GSK2248761 in Antiretroviral Therapy-Naive Subjects (SIGNET) Infection, Human Immunodeficiency Virus | Phase 2 | 2010-11-18 |
| Completed | ZIAGEN® Post-marketing Surveillance Infection, Human Immunodeficiency Virus I | — | 2010-11-01 |
| Completed | A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral Infection, Human Immunodeficiency Virus, HIV Infections | Phase 3 | 2010-10-26 |
| Completed | A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Infection, Human Immunodeficiency Virus I | Phase 3 | 2010-10-19 |
| Terminated | Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infec Infection, Human Immunodeficiency Virus | Phase 2 | 2010-10-05 |
| Completed | A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Amino Infections, Human Immunodeficiency Virus and Tuberculosis | Phase 1 | 2010-10-01 |
| Terminated | A Study to Evaluate the Pharmacokinetics of an Oral Contraceptive When Co-administered With GSK2248761 in Heal Infection, Human Immunodeficiency Virus, HIV Infections | Phase 1 | 2010-09-14 |
| Completed | GSK1349572 Drug Interaction Study With Fosamprenavir/Ritonavir Infections, Human Immunodeficiency Virus and Herpesviridae | Phase 1 | 2010-09-01 |
| Completed | A Single Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intramuscular a Infections, Human Immunodeficiency Virus and Herpesviridae | Phase 1 | 2010-09-01 |
| Completed | A Study to Assess the Relative Bioavailability of Tablet Formulations of GSK2248761 in Healthy Adult Subjects. Infections, Human Immunodeficiency Virus and Herpesviridae, Infection, Human Immunodeficiency Virus | Phase 1 | 2010-09-01 |
| Completed | Lamivudine(LAM) Good Responder Study Hepatitis B, Chronic | — | 2010-08-01 |
| Terminated | Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects Healthy | Phase 1 | 2010-07-01 |
| Completed | A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE) Infection, Human Immunodeficiency Virus | Phase 4 | 2010-04-01 |
| Completed | A Drug Interaction Study Evaluating GSK2248761 and Raltegravir Pharmacokinetics in Healthy Adult Subjects Infection, Human Immunodeficiency Virus | Phase 1 | 2010-04-01 |
| Completed | GSK1349572 Relative Bioavailability Study Infection, Human Immunodeficiency Virus | Phase 1 | 2010-04-01 |
| Completed | Safety And Efficacy Of Maraviroc In Patients For HIV Patients (Regulatory Post Marketing Commitment Plan) CCR5-tropic HIV-1 Infection | — | 2010-03-31 |
| Completed | GSK1349572 Drug Interaction Study With Efavirenz Infections, Human Immunodeficiency Virus and Herpesviridae | Phase 1 | 2010-03-16 |
| Completed | Effect Of Maraviroc On The Pharmacokinetics Of Digoxin Healthy, HIV Infections | Phase 1 | 2010-03-01 |
| Completed | Drug Interaction Study Between GSK1349572 and Tipranavir/Ritonavir in Healthy Volunteers Infection, Human Immunodeficiency Virus, HIV Infections | Phase 1 | 2010-02-15 |
| Completed | A Study to Assess Relative Bioavailability and Food Effect of New Formulations of GSK2248761 Infection, Human Immunodeficiency Virus, HIV Infections | Phase 1 | 2009-12-21 |
| Completed | Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068, an HIV Attachment Inhibitor, in HIV-1 HIV Infections | Phase 2 | 2009-11-23 |
| Completed | Safety and Tolerability Study to Evaluate Lower Dose of GSK2248761 in Antiretroviral Treatment-Naive HIV-1 Inf Infection, Human Immunodeficiency Virus | Phase 2 | 2009-10-20 |
| Completed | A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Ral Infection, Human Immunodeficiency Virus | Phase 2 | 2009-08-01 |
| No Longer Available | A Compassionate Access Protocol For Those Patients Who Have Completed A4001029 HIV | — | 2009-08-01 |
| Completed | A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects Infection, Human Immunodeficiency Virus | Phase 2 | 2009-07-30 |
| Completed | Non-Interventional Study Of Celsentri® In Treatment Experienced Patients With CCR5-Tropic HIV-Infection HIV-1 | — | 2009-07-01 |
| Completed | Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in HIV-1 Infected Adults (ITZ1129 Infection, Human Immunodeficiency Virus | Phase 2 | 2009-06-09 |
| Unknown | An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy F Human Immunodeficiency Virus | Phase 2 | 2009-04-22 |
| Completed | GSK1349572 Drug Interaction With Etravirine and Either Darunavir/Ritonavir or Lopinavir/Ritonavir Healthy Volunteer | Phase 1 | 2009-04-01 |
| Completed | HIV Cohort Study At Johns Hopkins University, University of North Carolina at Chapel Hill and Vanderbilt Unive HIV, AIDS | — | 2009-03-01 |
| Completed | HIV Treatment and CVD Events HIV Infection, Cardiovascular Disease, Infection, Human Immunodeficiency Virus | — | 2009-03-01 |
| Withdrawn | Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis C Hepatitis B, Human Immunodeficiency Virus, Hepatitis C, Chronic | Phase 4 | 2009-03-01 |
| Completed | A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-I Human Immunodeficiency Virus-1 | Phase 2 | 2009-03-01 |
| Completed | Investigation Of Safety And Pharmacokinetics Following A Single Oral Dose Of 300 Mg Maraviroc In Healthy Male Human Immunodeficiency Virus (HIV) Infection | Phase 1 | 2009-02-01 |
| Completed | Kaiser Permanente HIV Cohort Study HIV, AIDS | — | 2009-02-01 |
| Completed | PENTA Fosamprenavir Study Infection, Human Immunodeficiency Virus | — | 2008-10-01 |
| Withdrawn | Maraviroc Compassionate Use Human Immunodeficiency Virus Type 1 | Phase 3 | 2008-08-01 |
| Completed | Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Im Human Immunodeficiency Virus (HIV) Infection | Phase 4 | 2008-07-01 |
| Completed | Phase IIa Dose-ranging Study of GSK1349572 in HIV-1 Infected Adults Infection, Human Immunodeficiency Virus | Phase 2 | 2008-06-01 |
| Completed | Healthy Volunteer Study To Assess The Bioavailability of GSK1265744 When Administered Orally Either When Faste HIV Infection, Infection, Human Immunodeficiency Virus | Phase 1 | 2008-06-01 |
| Completed | Study To Investigate The Hemodynamic Effects Of Single Dose Vardenafil In Subjects Receiving Maraviroc AIDS | Phase 4 | 2008-04-01 |
| Completed | Prospective Observational Epidemiologic Study of Maraviroc's Safety Human Immunodeficiency Virus | — | 2008-03-31 |
| Completed | A Study To Evaluate An Interaction Between Maraviroc And Raltegravir In Healthy Subjects Healthy | Phase 4 | 2008-02-01 |
| Completed | GSK1349572 Repeat Dose Escalation and Relative Bioavailability Study Healthy Subjects | Phase 1 | 2008-02-01 |
| Terminated | Multicenter Pilot Study To Define The Marker As An Alternate For Tropism Assay HIV Infections | Phase 1 | 2007-07-01 |
| Completed | Multicenter, Safety Study Of Maraviroc Acquired Immunodeficiency Syndrome, HIV Infection | Phase 3 | 2007-07-01 |
| Completed | EuroSIDA As An External Comparator To MOTIVATE Trials HIV, AIDS | — | 2007-04-01 |
| Completed | Prospective Epidemiological Study Of The Prevalence Of HLA-B*5701 Infection, Human Immunodeficiency Virus | — | 2007-03-20 |
| Completed | Prospective Epidemiological Study Of The Prevalence Of HLAB*5701 In HIV-1 Infected Patients Infection, Human Immunodeficiency Virus | Phase 4 | 2007-03-15 |
| Completed | Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Inf Infection, Human Immunodeficiency Virus I, HIV Infection | Phase 3 | 2007-03-01 |
| Completed | HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in Antiretroviral Treatment Naive Ad Infection, Human Immunodeficiency Virus I, HIV-1 Infection | Phase 3 | 2007-03-01 |
| Completed | Expanded Access Program for Maraviroc At Multiple Centers HIV Infections | Phase 3 | 2007-02-01 |
| Completed | Fractures Stratified by HIV and Antiretroviral Therapy (ART) Status Fracture, Infection, Human Immunodeficiency Virus | — | 2006-11-01 |
| Terminated | A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibito Infection, Human Immunodeficiency Virus I, HIV-1 Infection | Phase 2 | 2005-08-01 |
| Terminated | Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Sub Infection, Human Immunodeficiency Virus I | Phase 3 | 2005-07-21 |
| Terminated | GW873140 In Combination With Combivir In HIV Infected Subjects Infection, Human Immunodeficiency Virus I, HIV Infection | Phase 2 | 2005-01-01 |
| Completed | Fosamprenavir Versus Other Protease Inhibitors Infection, Human Immunodeficiency Virus I | Phase 3 | 2004-12-14 |
| Terminated | GW873140 In Combination With Kaletra In HIV Infected Subjects Infection, Human Immunodeficiency Virus I, HIV Infection | Phase 2 | 2004-12-01 |
| Completed | Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background T HIV Infections | Phase 2 / Phase 3 | 2004-12-01 |
| Completed | Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background T HIV Infections | Phase 2 / Phase 3 | 2004-11-01 |
| Completed | Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background T HIV Infections | Phase 2 / Phase 3 | 2004-11-01 |
| Completed | Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With HIV-1 | Phase 3 | 2004-11-01 |
| Completed | GW640385 Plus Ritonavir And NRTIs For 48 Weeks In HIV-1 Infected Adults Infection, Human Immunodeficiency Virus I, HIV Infection | Phase 2 | 2004-10-01 |
| Completed | 48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infectio Infection, Human Immunodeficiency Virus I | Phase 2 | 2004-07-01 |
| Completed | Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects Infection, Human Immunodeficiency Virus, HIV Infections | Phase 2 | 2003-10-23 |
| Completed | Effects Of Food And Dose Regimen On The Antiviral Effects Of Maraviroc (UK-427,857) In Patients With Human Imm HIV | Phase 2 | 2003-07-01 |
| Completed | Fosamprenavir Expanded Access Infection, Human Immunodeficiency Virus | Phase 4 | 2003-07-01 |
| Completed | Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected Dur Infection, Human Immunodeficiency Virus I, HIV Infection | Phase 3 | 2003-06-01 |
| Completed | Pharmacokinetics, Pharmacodynamics, And Safety Of Maraviroc (UK-427,857) In Patients With Human Immunodeficien HIV Infections | Phase 2 | 2002-10-01 |
| Completed | A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced Patients Infection, Human Immunodeficiency Virus I, HIV Infection | Phase 3 | 2002-08-26 |
| Completed | New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Su Infection, Human Immunodeficiency Virus I, HIV Infection | Phase 3 | 2002-07-16 |
| Completed | A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2 HIV Infection | Phase 2 | 2002-07-01 |
| Completed | Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic HIV Infection | Phase 4 | 2002-03-01 |
| Completed | A Trial To Study The Effect Of Lamivudine In Adult Patients Who Suffer From Chronic Hepatitis B Alone CHRONIC HEPATITIS B | Phase 4 | 2002-02-09 |
| Completed | A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects Infection, Human Immunodeficiency Virus | Phase 3 | 2001-11-01 |
| No Longer Available | A Treatment Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Com Human Immunodeficiency Virus (HIV) | — | — |
| No Longer Available | An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc Infection, Human Immunodeficiency Virus | — | — |
| Available | GSK1265744 (Cabotegravir, CAB) for Named Patient/Compassionate Use in HIV Infection, Human Immunodeficiency Virus | — | — |
| Available | Fostemsavir Compassionate Use Named Patient Program for the Treatment of Human Immunodeficiency Virus 1 (HIV-1 HIV Infections | — | — |